Literature DB >> 17885725

Evidence for effectiveness of botulinum toxin for hyperhidrosis.

R Bhidayasiri1, D D Truong.   

Abstract

Hyperhidrosis refers to excessive and uncontrollable sweating beyond that is required to return body temperature to normal. Although a broad spectrum of treatment modalities are available including topical and systemic therapies, iontophoresis, and surgical interventions, their efficacy are usually short-term or are associated with unacceptable side effects. Recently, chemodenervation using botulinum toxin has emerged as a safe and effective treatment for both primary palmar and axillary hyperhidrosis in several clinical trials. In this article, we utilized the scale developed by the Therapeutics and Technology Assessment (TTA) subcommittee of the American Academy of Neurology evaluating current evidence supporting the use of botulinum toxin for the treatment of primary focal hyperhidrosis. As a result, there is a strong evidence to support the efficacy of botulinum toxin type A in axillary (Level A evidence) and palmar (Level B evidence) hyperhidrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885725     DOI: 10.1007/s00702-007-0812-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  42 in total

Review 1.  Evidence-based medicine: botulinum toxin in focal hyperhidrosis.

Authors:  M Naumann
Journal:  J Neurol       Date:  2001-04       Impact factor: 4.849

Review 2.  Expanding use of botulinum toxin.

Authors:  Roongroj Bhidayasiri; Daniel D Truong
Journal:  J Neurol Sci       Date:  2005-08-15       Impact factor: 3.181

Review 3.  Treatment of hyperhidrosis.

Authors:  L P Stolman
Journal:  Dermatol Clin       Date:  1998-10       Impact factor: 3.478

4.  Subcutaneous curettage vs. injection of botulinum toxin A for treatment of axillary hyperhidrosis.

Authors:  R Rompel; S Scholz
Journal:  J Eur Acad Dermatol Venereol       Date:  2001-05       Impact factor: 6.166

5.  An epidemiological study of hyperhidrosis.

Authors:  William Lear; Edward Kessler; Nowell Solish; Dee Anna Glaser
Journal:  Dermatol Surg       Date:  2007-01       Impact factor: 3.398

6.  Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.

Authors:  Leslie Baumann; Anele Slezinger; Monica Halem; Justin Vujevich; Karin Mallin; Carlos Charles; Lucy K Martin; Laura Black; Joy Bryde
Journal:  Dermatol Surg       Date:  2005-03       Impact factor: 3.398

7.  Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.

Authors:  M K Naumann; H Hamm; N J Lowe
Journal:  Br J Dermatol       Date:  2002-12       Impact factor: 9.302

8.  Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.

Authors:  Nicholas J Lowe; Dee Anna Glaser; Nina Eadie; Simon Daggett; Jonathan W Kowalski; Pan-Yu Lai
Journal:  J Am Acad Dermatol       Date:  2007-02-15       Impact factor: 11.527

9.  Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increase.

Authors:  T Karamfilov; H Konrad; K Karte; U Wollina
Journal:  Arch Dermatol       Date:  2000-04

Review 10.  Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type A.

Authors:  Dee Anna Glaser
Journal:  J Drugs Dermatol       Date:  2004 Nov-Dec       Impact factor: 2.114

View more
  7 in total

1.  Prediction of compensatory hyperhidrosis with botulinum toxin A and local anesthetic.

Authors:  Jin Yong Jeong; Soo Seog Park; Sung Bo Sim; Keon Hyon Jo; Jongho Lee; Saecheol Oh; Jae Seong Shin
Journal:  Clin Auton Res       Date:  2015-05-08       Impact factor: 4.435

2.  Botulinum toxin abolishes sweating via impaired sweat gland responsiveness to exogenous acetylcholine.

Authors:  M Shibasaki; S L Davis; J Cui; D A Low; D M Keller; C G Crandall
Journal:  Br J Dermatol       Date:  2009-04-22       Impact factor: 9.302

3.  Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin.

Authors:  B M Torrisi; V Zarnitsyn; M R Prausnitz; A Anstey; C Gateley; J C Birchall; S A Coulman
Journal:  J Control Release       Date:  2012-11-23       Impact factor: 9.776

4.  Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2010

5.  Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Authors:  Jürgen Frevert; Dirk Dressler
Journal:  Biologics       Date:  2010-12-09

6.  Immunogenicity of botulinum toxin.

Authors:  Syeo Young Wee; Eun Soo Park
Journal:  Arch Plast Surg       Date:  2022-01-15

7.  Thoracoscopic sympathetic block to predict compensatory hyperhidrosis in primary hyperhidrosis.

Authors:  June Lee; Jin Yong Jeong; Jong Hui Suh; Chan Beom Park; Hana Kwoun; Soo Seog Park
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.